Despite reaching remission with traditional chemotherapy, most adult patients with acute
myeloid leukemia (AML) will relapse and die of their disease. Numerous studies have …

Simple Summary Gemtuzumab Ozogamicin (GO) is a drug approved for the treatment of
acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on …

Introduction: Gemtuzumab ozogamicin (GO) is a combination of calicheamicin and a
recombinant humanized IgG4 antibody directed against CD33. From 2000 to 2010, it was …

Abstract On February 22, 2018, the Committee for Medicinal Products for Human Use
(CHMP) adopted a positive opinion, recommending the granting of a marketing …

Gemtuzumab ozogamicin (GO, Mylotarg®) consists of a humanized CD33-targeted antibody-
drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute …

The prognosis of acute myeloid leukemia, particularly when associated with adverse
chromosomal or molecular aberrations, is poor due to a high relapse rate after induction …

Background Qualitative and quantitative defects in natural killer (NK) cells have been noted
in patients with acute myeloid leukemia (AML), providing rationale for infusion of donor …

Introduction Induction chemotherapy based on anthracyclines and cytarabine (Ara-C)
combination remains the standard of care for acute myeloid leukemia (AML) patients who …

Survival rates for children with acute myeloid leukemia (AML) exceed 60% when modern,
intensified chemotherapeutic regimens and enhanced supportive care measures are …

Gemtuzumab ozogamicin (fGO), a humanized anti‐CD33 monoclonal antibody linked to
calicheamicin in combination with intensive chemotherapy gives high response rates in …